EP0257956B2
(fr)
|
1986-08-19 |
2000-11-22 |
Genentech, Inc. |
Usage de facteurs de croissance et de cytocines polypeptides pour fabriquer un dispositif et une dispersion
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
US6582728B1
(en)
*
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
US5661125A
(en)
*
|
1992-08-06 |
1997-08-26 |
Amgen, Inc. |
Stable and preserved erythropoietin compositions
|
US6012450A
(en)
*
|
1993-01-29 |
2000-01-11 |
Aradigm Corporation |
Intrapulmonary delivery of hematopoietic drug
|
ATE264096T1
(de)
|
1994-03-07 |
2004-04-15 |
Nektar Therapeutics |
Verfahren und mittel zur verabreichung von insulin über die lunge
|
US6051256A
(en)
*
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
AU696387B2
(en)
|
1994-05-18 |
1998-09-10 |
Inhale Therapeutic Systems, Inc. |
Methods and compositions for the dry powder formulation of interferons
|
US6586006B2
(en)
|
1994-08-04 |
2003-07-01 |
Elan Drug Delivery Limited |
Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
|
US6290991B1
(en)
*
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
IL116085A
(en)
*
|
1994-12-16 |
1999-12-31 |
Ortho Pharma Corp |
Spray dried erythropoietin
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
EP0817655B1
(fr)
*
|
1995-03-31 |
2004-05-19 |
Aradigm Corporation |
Administration intrapulmonaire d'un medicament hematopoietique
|
KR19980703876A
(ko)
*
|
1995-04-14 |
1998-12-05 |
스티븐 엘. 허스트 |
분산성이 개선된 분말화된 약학적 조성물
|
US5869451A
(en)
|
1995-06-07 |
1999-02-09 |
Glaxo Group Limited |
Peptides and compounds that bind to a receptor
|
BR9608587A
(pt)
|
1995-06-07 |
1999-01-05 |
Glaxo Group Ltd |
Composto que se liga ao receptor de trombopoietina composição farmacêutica e processo para o tratamento de um paciente sofrendo de um distúrbio
|
DE19539574A1
(de)
*
|
1995-10-25 |
1997-04-30 |
Boehringer Mannheim Gmbh |
Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
|
US5875776A
(en)
*
|
1996-04-09 |
1999-03-02 |
Vivorx Pharmaceuticals, Inc. |
Dry powder inhaler
|
DE69724420T2
(de)
*
|
1996-04-29 |
2004-06-09 |
Quadrant Technologies Ltd. |
Verfahren zum inhalieren trockener pulver
|
US7091311B2
(en)
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
GB9612297D0
(en)
*
|
1996-06-11 |
1996-08-14 |
Minnesota Mining & Mfg |
Medicinal aerosol formulations
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
DE19733651A1
(de)
*
|
1997-08-04 |
1999-02-18 |
Boehringer Ingelheim Pharma |
Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
DE69814428T2
(de)
†
|
1997-09-29 |
2004-05-13 |
Nektar Therapeutics, San Carlos |
In verneblern verwendbare, stabilisierte zubereitungen
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
USRE40911E1
(en)
|
1998-04-22 |
2009-09-08 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
WO2000067769A1
(fr)
|
1999-05-11 |
2000-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Ameliorations de la survie des patients souffrant du cancer traites avec de l'erythropoietine et des agents antitumoraux
|
US7668658B2
(en)
|
1999-10-13 |
2010-02-23 |
Sequenom, Inc. |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
EP1230349B1
(fr)
|
1999-11-18 |
2007-06-13 |
Dendreon Corporation |
Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
|
CZ20022265A3
(cs)
*
|
1999-12-30 |
2004-01-14 |
Chiron Corporation |
Léčivo pro podávání interleukinu-2 a stabilizovaný lyofilizovaný nebo sprejově sušený farmaceutický prostředek s obsahem interleukinu-2
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
MXPA02001323A
(es)
|
2000-05-10 |
2004-07-16 |
Alliance Pharma |
Microgranulos con base fosfolipida para la liberacion de farmaco.
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
BRPI0110914B8
(pt)
*
|
2000-05-15 |
2021-05-25 |
Hoffmann La Roche |
'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
AU1850302A
(en)
*
|
2000-11-29 |
2002-06-11 |
Itoham Foods Inc |
Powdery preparations and proecss for producing the same
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
PT1471871E
(pt)
*
|
2001-02-02 |
2007-06-05 |
Ortho Mcneil Pharm Inc |
Tratamento de disfunção neurológica compreendendo sulfamatos de frutopiranose e eritropoietina
|
US20030072717A1
(en)
*
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
WO2002072786A2
(fr)
|
2001-03-13 |
2002-09-19 |
Corvas International, Inc. |
Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
KR20040011480A
(ko)
|
2001-03-22 |
2004-02-05 |
덴드레온 샌 디에고 엘엘씨 |
세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
DK1389137T3
(da)
*
|
2001-05-21 |
2006-10-30 |
Injet Digital Aerosols Ltd |
Sammensætninger til lungelægemiddellevering af protein
|
EG24184A
(en)
*
|
2001-06-15 |
2008-10-08 |
Otsuka Pharma Co Ltd |
Dry powder inhalation system for transpulmonary
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
US7368102B2
(en)
|
2001-12-19 |
2008-05-06 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
WO2003055526A2
(fr)
*
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Conjugues d'erythropoietine
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
EP1501863A4
(fr)
|
2002-05-03 |
2007-01-24 |
Sequenom Inc |
Muteines de proteines d'ancrage de kinase, leurs peptides, et procedes associes
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US20040009908A1
(en)
*
|
2002-07-10 |
2004-01-15 |
Stamler Jonathan S. |
Methods for treating or preventing ischemic injury
|
DE10234192B4
(de)
*
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
NZ566812A
(en)
|
2002-09-18 |
2009-07-31 |
Ortho Mcneil Pharm Inc |
Methods of increasing platelet and hematopoietic stem cell production
|
EP1852441B1
(fr)
|
2002-09-24 |
2012-03-28 |
The Burnham Institute |
Agents qui modulent l'activité du récepteur EPH
|
WO2004047768A2
(fr)
*
|
2002-11-26 |
2004-06-10 |
Seacoast Neuroscience, Inc. |
Articles polymeres flottants pour l'administration d'agents therapeutiques au systeme nerveux central
|
US20040132645A1
(en)
*
|
2003-01-03 |
2004-07-08 |
Knox Susan J. |
Methods for modulating effects of radiation in a subject
|
JP4723476B2
(ja)
|
2003-02-14 |
2011-07-13 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
|
AU2004229465B2
(en)
*
|
2003-04-09 |
2010-04-29 |
The United States Of America Department Of Veterans Affairs |
Compositions and methods related to production of erythropoietin
|
DE102004004509B4
(de)
*
|
2004-01-23 |
2010-07-01 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
WO2006089228A2
(fr)
*
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugues d'une fraction d'epo et d'un polymere
|
US8000981B2
(en)
|
2005-11-30 |
2011-08-16 |
The Invention Science Fund I, Llc |
Methods and systems related to receiving nutraceutical associated information
|
US7827042B2
(en)
|
2005-11-30 |
2010-11-02 |
The Invention Science Fund I, Inc |
Methods and systems related to transmission of nutraceutical associated information
|
US8340944B2
(en)
|
2005-11-30 |
2012-12-25 |
The Invention Science Fund I, Llc |
Computational and/or control systems and methods related to nutraceutical agent selection and dosing
|
US7927787B2
(en)
|
2006-06-28 |
2011-04-19 |
The Invention Science Fund I, Llc |
Methods and systems for analysis of nutraceutical associated components
|
US10296720B2
(en)
|
2005-11-30 |
2019-05-21 |
Gearbox Llc |
Computational systems and methods related to nutraceuticals
|
US7974856B2
(en)
|
2005-11-30 |
2011-07-05 |
The Invention Science Fund I, Llc |
Computational systems and methods related to nutraceuticals
|
US8068991B2
(en)
|
2005-11-30 |
2011-11-29 |
The Invention Science Fund I, Llc |
Systems and methods for transmitting pathogen related information and responding
|
US8297028B2
(en)
|
2006-06-14 |
2012-10-30 |
The Invention Science Fund I, Llc |
Individualized pharmaceutical selection and packaging
|
TW200810773A
(en)
*
|
2006-04-19 |
2008-03-01 |
Alba Therapeutics Corp |
Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
|
KR101476458B1
(ko)
|
2006-07-05 |
2015-01-05 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
EP2120875B1
(fr)
|
2007-02-11 |
2018-07-11 |
Map Pharmaceuticals Inc. |
Procédé d'administration thérapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
|
TWI784538B
(zh)
|
2008-08-14 |
2022-11-21 |
美商艾瑟勒朗法瑪公司 |
使用gdf阱以增加紅血球水平
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
EP3875104A1
(fr)
*
|
2011-10-17 |
2021-09-08 |
Acceleron Pharma Inc. |
Procédés et compositions pour traiter de la myélofibrose
|
KR101855242B1
(ko)
|
2012-01-26 |
2018-05-09 |
크리스토퍼 제이. 소레스 |
펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
WO2015136527A1
(fr)
|
2014-03-10 |
2015-09-17 |
Health Corporation - Rambam |
Peptides inhibiteurs de l'héparanase et leur utilisation pour le traitement de pathologies cliniques
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
WO2018045083A1
(fr)
|
2016-09-02 |
2018-03-08 |
Soares Christopher J |
Utilisation d'antagonistes du récepteur cgrp en neuroprotection et pour le traitement de troubles neurologiques
|
CA3070442A1
(fr)
|
2017-07-26 |
2019-01-31 |
Janssen Pharmaceutica Nv |
Procedes de protection de l'integrite vasculaire induite par une radiotherapie ciblee
|
JP2022523663A
(ja)
|
2019-01-25 |
2022-04-26 |
ヤンセン ファーマシューティカ エヌ.ベー. |
放射線処置および/または放射線模倣剤処置を伴う、肝損傷を緩和し、肝臓の肥厚、再生、および細胞の生着を促進するための方法
|
KR20210120037A
(ko)
|
2019-01-25 |
2021-10-06 |
잔센파마슈티카엔.브이. |
수포제 및 가성 가스의 독성 영향 경감 방법
|
WO2020154637A1
(fr)
|
2019-01-25 |
2020-07-30 |
Janssen Pharmaceutica Nv |
Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
|
CN113939307A
(zh)
|
2019-03-29 |
2022-01-14 |
皮里斯制药有限公司 |
脂质运载蛋白突变蛋白的吸入施用
|
US20220273792A1
(en)
|
2019-08-01 |
2022-09-01 |
Acm Biolabs Pte Ltd |
A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
|
AU2021260857A1
(en)
|
2020-04-24 |
2022-11-03 |
Acm Biolabs Pte Ltd |
Vaccine against human-pathogenic coronaviruses
|
AU2021396659A1
(en)
|
2020-12-11 |
2023-05-04 |
Acm Biolabs Pte Ltd |
Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
|
CA3204785A1
(fr)
|
2021-02-02 |
2022-08-11 |
Madhavan Nallani |
Utilisation seule de polymerosome associe a un adjuvant pour stimuler une reponse immunitaire
|
KR20230165917A
(ko)
|
2021-04-08 |
2023-12-05 |
피어이스 파마슈티컬즈 게엠베하 |
결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
|
CA3234340A1
(fr)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica N.V. |
Procedes d'augmentation de la production de cellules progenitrices
|
WO2023168426A1
(fr)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions et cellules contenant des mélanges de protéines de fusion oligo-trap (ofps) et leurs utilisations
|